EQRx, Inc.

EQRx, Inc. (Nasdaq: EQRX) is a biopharmaceutical company that entered the public markets through a merger with CMLS Holdings, a blank-check company sponsored by TPG that completed its IPO in 2021. The de-SPAC transaction closed in late 2022, bringing EQRx's strategy of developing and commercializing lower-cost innovative medicines to the public stage. The company filed an 8-K with the SEC on August 1, 2023, under accession number 0001193125-23-199916, disclosing a material corporate event during a period of active strategic review within the healthcare SPAC sector. For full filing history, sponsor details, and deal analytics on EQRX and hundreds of other SPAC transactions, sign up for complete data access at SpacDesk.